AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 NOV 4 - (NewsRx.com & NewsRx.net) -- ParAllele BioScience announced that it has entered into collaboration with Novartis Pharma AG to discover genetic variations associated with coronary artery disease.
Coronary artery disease affects 13 million people in the United States and is the leading cause of death for both men and women. The results of the study will be used to identify biomarkers that can aid disease diagnosis and potentially guide treatment options, as well as identify and prioritize new drug targets.
In this Novartis-funded study, ParAllele will utilize its proprietary Mismatch Repair Detection (MRD) technology to comprehensively discover novel Single Nucleotide Polymorphisms (SNPs) in candidate genes selected by Novartis. These SNPs will be profiled across a large population of coronary artery disease patients and matched control samples to identify associations between SNPs and the disease. Novartis will utilize these markers in drug discovery and ParAllele will retain rights for diagnostic applications. Financial terms of the agreement were not disclosed.
"We are pleased to collaborate with Novartis in order to discover the key risk factors and causative mutations for coronary artery disease," said Nick Naclerio, PhD, ParAllele's President and CEO. "We hope our results will translate into earlier detection and better treatment options for this most common form ...